Biotech | April 05, 2022
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction
The Drug Registry intends to create a nationally recognized source of information on various systems of medicine in the country
Yashoda Hospitals Hyderabad has earned the distinction of becoming the first to introduce BTVA in India
BVX-0922 to target colorectal cancer under investigator-sponsored IND
Subscribe To Our Newsletter & Stay Updated
